Antibody-drug conjugates and bispecifics featured strongly at ASCO this year, with Chinese companies putting on a major showing in each area and overall at the Chicago meeting.
Innovent Biologics was among those presenting data, including from four trials with IBI363, its PD-1/IL-2α-bias-targeting bispecific. Three, in advanced NSCLC, melanoma and colorectal cancer, showed promising OS outcomes.
The Chinese firm's CEO noted in an interview with Scrip that Innovent is also continuing to build up its in-house pipeline in metabolic diseases, with the first clinical readouts for IBI3030, a GGG/PCSK9 antibody-peptide conjugate, due next year.
The executive also emphasized the importance of overall survival data in gaining approval, particularly for later-line treatments, regardless of the regulator.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

Presents At ASCO On Multiple Assets